Then read the method: Claude drove the specialist design tools the field already ships, and a binder is the first step of a drug, not the drug.
“Anthropic says Claude designed protein binders against 14 of 15 targets, with 22 to 35 percent of individual designs binding successfully versus the 10 to 15 percent typical in protein design campaigns today, results independently produced and tested in the lab by Adaptyv Bio and Twist Bioscience.”
Anthropic (protein design research post, August 18), 18 August 2026
Recorded 19 August 2026. Our ruling means: literally true, materially misleading.
Between 22% and 35% of its individual designs bound successfully, depending on the setup, compared to the 10-15% that is typical in protein design campaigns today.
RFdiffusion has demonstrated outstanding performance in designing picomolar-affinity helical peptide minibinders, symmetric structural assemblies, and various minibinders targeting antigens such as GAPD and TNFR
First membership: 30 days free, then A$89 a year. One introductory trial per customer. Card required; renews annually until cancelled. Cancel before the trial ends to avoid the first charge.
Free · one story a night
Don't take the AI industry's word for it.
“AI is dramatically accelerating AI research at Anthropic right now, roughly doubling the pace of capabilities progress.”
TRUE, BUTLab Not FieldAjeya Cotra on Planned Obsolescence, reading METR's assessment and Anthropic's S-1 statement that it may imminently meet its own threshold
That's the latest lead check. One a day, receipts attached, in your inbox before someone repeats it at you. Free.
No spam. Unsubscribe in one click. Receipts or it didn't happen.
Pranjal Gupta writes every check himself. Former enterprise architect, from the implementation side. Not a team of anonymous raters.
